Literature DB >> 11429397

Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects.

L J Landells1, C M Szilagy, N A Jones, K H Banner, J M Allen, A Doherty, B J O'Connor, D Spina, C P Page.   

Abstract

In the present study, for the first time, PDE4 subtypes were identified and semi-quantified in both CD4 and CD8 lymphocytes from healthy and asthmatic individuals. CD4 and CD8 lymphocytes from healthy and mild asymptomatic asthmatic subjects (receiving beta-agonist therapy only) were isolated from peripheral venous blood using appropriate antibody coated paramagnetic beads. PDE4 subtypes and beta-actin were identified by digoxigenin (DIG)-labelling reverse transcriptase-polymerase chain reaction and semi-quantified by DIG-detection enzyme-linked immunosorbance assay. In CD4 and CD8 lymphocytes PDE4A, PDE4B and PDE4D were detected, with no significant differences observed between healthy and asthmatic groups. In CD8 lymphocytes, enzyme subtype expression was lower and showed more intersubject variability. In functional studies investigating the effects of various PDE inhibitors on PHA-induced proliferation of mononuclear cells from healthy and asthmatic subjects, CDP840 (0.03 - 10 microM), rolipram (0.1 - 10 microM) and theophylline (10 microM - 1 mM) inhibited PHA-induced proliferation of mononuclear cells from healthy and asthmatic subjects in a concentration-dependent manner, although no significant difference was observed between the groups investigated. In additional studies, total monocyte cyclic AMP PDE activity was investigated in cells isolated from asthmatic subjects both prior to and 24 h after allergen challenge. Total monocyte cyclic AMP PDE activity remained unaffected following challenge of asthmatic subjects with either house dust mite or cat dander and was inhibited in a concentration-dependent manner by rolipram (0.01 - 100 microM) both before and after allergen challenge.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11429397      PMCID: PMC1572832          DOI: 10.1038/sj.bjp.0704120

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  A biochemical and functional assessment of monocyte phosphodiesterase activity in healthy and asthmatic subjects.

Authors:  L J Landells; D Spina; J E Souness; B J O'Connor; C P Page
Journal:  Pulm Pharmacol Ther       Date:  2000       Impact factor: 3.410

Review 2.  Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?

Authors:  M A Giembycz
Journal:  Biochem Pharmacol       Date:  1992-05-28       Impact factor: 5.858

Review 3.  Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme.

Authors:  W J Thompson; W L Terasaki; P M Epstein; S J Strada
Journal:  Adv Cyclic Nucleotide Res       Date:  1979

4.  CD3- and CD28-dependent induction of PDE7 required for T cell activation.

Authors:  L Li; C Yee; J A Beavo
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

5.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

6.  Striatum- and testis-specific phosphodiesterase PDE10A isolation and characterization of a rat PDE10A.

Authors:  K Fujishige; J Kotera; K Omori
Journal:  Eur J Biochem       Date:  1999-12

7.  Expression and regulation of human and rat phosphodiesterase type IV isogenes.

Authors:  P Engels; K Fichtel; H Lübbert
Journal:  FEBS Lett       Date:  1994-08-22       Impact factor: 4.124

8.  Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness.

Authors:  S R Grewe; S C Chan; J M Hanifin
Journal:  J Allergy Clin Immunol       Date:  1982-12       Impact factor: 10.793

9.  Phosphatidic acid stimulates the rolipram-sensitive cyclic nucleotide phosphodiesterase from rat thymocytes.

Authors:  P Marcoz; G Némoz; A F Prigent; M Lagarde
Journal:  Biochim Biophys Acta       Date:  1993-03-10

10.  Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis.

Authors:  S C Chan; D Reifsnyder; J A Beavo; J M Hanifin
Journal:  J Allergy Clin Immunol       Date:  1993-06       Impact factor: 10.793

View more
  10 in total

Review 1.  Phosphodiesterase inhibitors.

Authors:  Victoria Boswell-Smith; Domenico Spina; Clive P Page
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

2.  Genomic implications of H(2)O (2) for cell proliferation and growth of Caco-2 cells.

Authors:  Theresa A Herring; Susan L Cuppett; Janos Zempleni
Journal:  Dig Dis Sci       Date:  2007-06-28       Impact factor: 3.199

3.  Associations between SNP83 of phosphodiesterase 4D gene and carotid atherosclerosis in a southern Chinese Han population: a case-control study.

Authors:  Liu-Yu Liu; Dong-Can Mo; Jian-Li Li; Yi-Ying Jiang; Guo-Qiu Zhou; Dong-Dong Jiang; Li-Jie Chen; Xiao-Ju Wu; Jiao-Xing Li; Man Luo
Journal:  Mamm Genome       Date:  2021-03-23       Impact factor: 2.957

4.  Phosphodiesterase 4D single-nucleotide polymorphism 83 and cognitive dysfunction in carotid endarterectomy patients.

Authors:  Eric J Heyer; Joanna L Mergeche; Justin T Ward; Hani R Malone; Christopher Kellner; Samuel S Bruce; E Sander Connolly
Journal:  Neurosurgery       Date:  2013-11       Impact factor: 4.654

Review 5.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease.

Authors:  Katharine H Banner; Neil J Press
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

7.  Effects of inactivated Bordetella pertussis on phosphodiesterase in the lung of ovalbumin sensitized and challenged rats.

Authors:  Ya-Juan Wang; Shun-De Song; Jun-Chun Chen; Xue-Feng Wang; Ya-Li Jiang; Qiang-Min Xie; Ji-Qiang Chen; Zi-Gang Li; Hui-Fang Tang
Journal:  Pulm Med       Date:  2014-07-09

8.  Liquiritigenin enhances cyclic adenosine monophosphate production to mitigate inflammation in dendritic cells.

Authors:  Mingming Qin; Aili Guo; Feng Li; Fuxiang Zhang; Meirong Bi; Yamin Zhang; Weiwei Zhu
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

Review 9.  PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.

Authors:  Victoria Boswell-Smith; Domenico Spina
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  New drugs targeting Th2 lymphocytes in asthma.

Authors:  Gaetano Caramori; David Groneberg; Kazuhiro Ito; Paolo Casolari; Ian M Adcock; Alberto Papi
Journal:  J Occup Med Toxicol       Date:  2008-02-27       Impact factor: 2.646

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.